American multinational independent investment bank and financial services company
Raymond James Financial, Inc. is an American multinational independent investment bank and financial services company providing financial services to individuals, corporations, and municipalities through its subsidiary companies that engage primarily in investment and financial planning, in addition...
Palvella Therapeutics has seen a 346% surge in its stock price over the past year, and a Strong Buy rating from Raymond James with a $193 target underscores growing confidence in its Phase 3 trial results. The company’s potential approval of a novel treatment for microcystic lymphatic malformation could open a new market and drive further upside for investors.
Context & Background
Phase 3 trial bar raised to a mean mLM-IGA score of at least +1.0, up from +0.5
Stock has surged 346% in the last year to $85.66 with a market cap of $1.01 billion
All covering analysts maintain a Strong Buy consensus with price targets ranging from $143 to $212
Breakthrough Therapy Designation granted by the FDA for QTORIN rapamycin
Upcoming March readout expected to provide data on efficacy and safety
What Happens Next
The March readout will be critical in confirming the efficacy of Palvella’s QTORIN therapy and could lead to FDA approval, potentially boosting the stock further. Investors will closely monitor secondary endpoints and imaging data to assess the likelihood of market uptake.
Frequently Asked Questions
What is the significance of the new Phase 3 bar?
The higher bar indicates a more stringent efficacy threshold, which, if met, strengthens the case for regulatory approval and physician adoption.
How might the March readout affect the stock price?
Positive results could lift the stock, while negative or inconclusive data might cause a decline.
What other therapies is Palvella developing?
Palvella is also advancing QTORIN for porokeratosis, with Phase 2 expected in the second half of 2026.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Five things to watch in markets in the week ahead Trump’s 15% global tariff; Waller to speak; oil drops - what’s moving markets U.S. stock futures drop on Trump tariff turmoil; Nvidia earnings in spotlight Novo Nordisk and Netflix fall premarket; Eli Lilly and Domino’s Pizza rise (South Africa Philippines Nigeria) Raymond James reiterates Strong Buy on Palvella stock, $193 target By Investing.com Analyst Ratings Published 02/23/2026, 07:47 AM Raymond James reiterates Strong Buy on Palvella stock, $193 target 0 PVLA 4.04% Investing.com - Raymond James reiterated a Strong Buy rating on Palvella Therapeutics (NASDAQ:PVLA) with a $193.00 price target. The optimism aligns with broader analyst sentiment, as all covering analysts maintain a Strong Buy consensus with price targets ranging from $143 to $212. The stock has surged 346% over the past year, trading at $85.66 with a market capitalization of $1.01 billion. The firm noted that Palvella increased its internal bar for a decisive win in its Phase 3 MLM program to a mean mLM-IGA score of at least +1.0 from at least +0.5. The company’s upside case is set at at least +1.5. Raymond James said the new bar came as a surprise to many investors given the distance from the +2.4 mean CGI-C result seen in Phase 2. The firm said Palvella’s bar is likely adequate to support approval and physician utilization as long as other secondary endpoints, images and interviews show a similarly positive trend. The longer study duration and data-rich expected readout will provide opportunities to convince investors of QTORIN rapamycin’s treatment benefit at topline, according to Raymond James. The firm said it is walking through its thinking on Palvella’s rationale for its bar in MLM, buyside expectations for the SELVA topline readout, and what to expect from the data readout expected in March. While InvestingPro analysis suggests the stock is currently overvalued relative to its Fair ...
